期刊文献+

红花抗肿瘤之应用与作用机理探析 被引量:13

Discussion of Safflower Inhibiting Tumor in Application and Its Mechanism of Action
暂未订购
导出
摘要 介绍红花抗肿瘤在临床上的常见应用,指出红花多用于复方配伍使用及适用于肿瘤血瘀证;以及探析了红花抗肿瘤可能的作用机理,指出红花可能是通过直接抑制肿瘤血管生成、协同增效等效应发挥作用的,以期为进一步深入研究红花及其组分的抗癌机制打下基础。 The article introduces the clinical common application of safflower in tumor, points out that safflower usually uses in complex prescription and to the syndrome of blood stasis, and also discusses the potential mechanism of its action to antagonize tumor, indicates that the safflower may show its action to inhibit tumor ceils through synergy, direct repression to tumor angiogenesis, and so on. Then we expect to establish one foundation to further lucubrate the anticancer mechanism of safflower and its active components.
出处 《中华中医药学刊》 CAS 2008年第9期1916-1917,共2页 Chinese Archives of Traditional Chinese Medicine
基金 国家自然科学基金资助项目(30572436)
关键词 红花 肿瘤 应用 作用机理 safflower tumor application mechanism of action
  • 相关文献

参考文献9

二级参考文献22

  • 1[4]Hanada D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch duriog tumorigenesis. Cell, 1996, 86 (3):353
  • 2张前,牛欣,解华,等.中药抑制新生血管生成的实验研究[J].中国医药学报,2002,17(增刊):180.
  • 3[9]Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci USA, 1979, 76(10): 5217
  • 4Cao Y,O'Reilly MS,Marshall B,et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest,1998,101(5):1055-1063
  • 5Nelson NJ. Angiogenesis research is on fast forward. J Natl Cancer Inst,1999,91(10):820-822
  • 6Mukhopadhyay D,Nagy JA, Manseau EJ,et al. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res,1998,58(6): 1278-1284
  • 7Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996,86:353
  • 8Presta LG,Chen H,O'Connor SJ,et al. Humanization of anti-vascular endothelial growth factor monoclonal antibody for therapy of solid tumors and other disorders. Cancer Res,1997,57(20):4593-4599
  • 9Belotti D, Paganoni P, Giavazzi R. MMP inhibitors:experimental and clinical studies. Int J Biol Markes, 1999, 14(4):232-238
  • 10Small EJ,Meyer M,Marshall ME,et al. Suramin therapy for patients with symptomatic hormone refractory prostate cancer:results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J.Clin Oncol, 2000,18(7): 14

共引文献97

同被引文献127

引证文献13

二级引证文献196

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部